Krystexxa

 

Topic mentions per year

Topic mentions per year

2010-2018
0120102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
  • JAMA
  • 2018
Standard Treatment Recent guidelines offer conflicting views on the benefits of monitoring serum uric acid levels and the… (More)
Is this relevant?
Review
2013
Review
2013
  • Nature Biotechnology
  • 2013
1 2012 was not a banner year for sales of newly launched biotech drugs. Revenues of Regeneron’s decoy receptor Zaltrap were… (More)
Is this relevant?
Review
2012
Review
2012
OBJECTIVE To evaluate efficacy and safety of pegloticase, approved by the Food and Drug Administration in September 2010 for… (More)
  • table 1
  • table 2
Is this relevant?
2011
2011
  • 2011
SUPPLEMENT 2011 ANNUAL SCIENTIFIC MEETING November 4–9, 2011 Chicago, Illinois AN OFFICIAL JOURNAL OF THE AMERICAN COLLEGE OF… (More)
Is this relevant?
2010
2010
In September 2010, pegloticase (Krystexxa; Savient Pharmaceuticals), a recombinant urate oxidase conjugated to polyethylene… (More)
  • figure 1
Is this relevant?